About BenevolentAI

BenevolentAI, founded in 2013, is an AI company developing and applying advanced technologies to accelerate the journey from data to medicine.

The company combines the power of computational medicine and advanced AI with the principles of open systems and cloud computing to transform the way drugs are designed, developed, tested and brought to market. The company has developed the ‘Benevolent Platform’, the world’s only end-to-end computational and experimental platform for drug discovery that’s spans data ingestion to clinical development

BenevolentAI is HQ’d in London with a research facility in Cambridge (UK) and further offices in New York and Belgium. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson’s, Ulcerative Colitis and Sarcopenia.

“From our perspective diversity is about positively adopting people’s differences, no matter what they may be. Prejudice isn’t just morally wrong, it is commercially senseless too. If you want to build a company with the brightest talent from around the world – why deny your business access to the best brains based on bias and discrimination. True innovation comes from celebrating diversity, where different minds collide and work together towards a shared ambition.”

– James Chandler, VP Corporate Affairs, BenevolentAI